Berman Capital Advisors’s Sutro Biopharma STRO Stock Holding History

Berman Capital Advisors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10	Closed	–	–	1762
2020 Q2	$0	Buy	+10	New	+$960	﹤0.01%	1804

Other funds holding STRO

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Berman Capital Advisors's STRO Position: Q3 2020 in Review

Berman Capital Advisors sold out of Sutro Biopharma (STRO) in Q3 2020, closing a stake of 10 shares.

Berman Capital Advisors first reported a position in STRO in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 86 funds tracked by Wall St. Rank hold STRO as of Q3 2020.

Berman Capital Advisors reported no remaining Sutro Biopharma position as of Q3 2020 after selling out during the quarter.
Berman Capital Advisors sold 10 Sutro Biopharma shares in Q3 2020.
Berman Capital Advisors first reported a position in Sutro Biopharma in Q2 2020 and held it in 1 quarter.
Berman Capital Advisors's Sutro Biopharma position peaked at $0 in Q2 2020.
86 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2020.

Based on Berman Capital Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.